Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.30 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.30 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18187875 | 1.00 | MAPT (0.32) | MAPTACEGABRA1GABRA5GABRB2 | |
| SCHEMBL9182934 | 0.88 | PSMB1 (0.35) | ACE | |
| SCHEMBL12837727 | 0.82 | MAPT (0.31) | MAPT | |
| SCHEMBL13259646 | 0.79 | SLC7A5 (0.31) | — | |
| SCHEMBL10836267 | 0.79 | MAPT (0.39) | MAPT | |
| SCHEMBL3401832 | 0.78 | MAPT (0.30) | MAPT | |
| SCHEMBL11544417 | 0.77 | — | — | |
| SCHEMBL11546128 | 0.77 | — | — | |
| SCHEMBL23466931 | 0.76 | ALDH1A1 (0.43) | MAPT | |
| SCHEMBL22279575 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160318862-A1 | SYNTHESIS OF DELTA 12-PGJ3 AND RELATED COMPOUNDS | WILLIAM MARSH RICE UNIVERSITY (US) | 2016-11-03 | — | — | US | disclosed |
| US-7196078-B2 | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPOARTION (US) | 2007-03-27 | — | — | US | disclosed |
| US-6008398-A | Non-nucleotide phosphorus ester oligomers | GENZYME CORPORATION (US) | 1999-12-28 | — | — | US | disclosed |
| US-5919965-A | Non-nucleotide phosphorus ester oligomers | GENZYME CORPORATION (US) | 1999-07-06 | — | — | US | disclosed |
| EP-0880532-A4 | NON-NUCLEOTIDE PHOSPHOROUS ESTER OLIGOMERS | PHARMAGENICS INC (US) | 1999-06-09 | — | — | EP | disclosed |
| EP-0880532-A1 | NON-NUCLEOTIDE PHOSPHOROUS ESTER OLIGOMERS | PHARMAGENICS, INC. (US) | 1998-12-02 | — | — | EP | disclosed |
| EP-0804443-A4 | NON-NUCLEOTIDE PHOSPHORUS ESTER OLIGOMERS | PHARMAGENICS INC (US) | 1998-04-29 | — | — | EP | disclosed |
| EP-0804443-A1 | NON-NUCLEOTIDE PHOSPHORUS ESTER OLIGOMERS | PHARMAGENICS, INC. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1997028168-A1 | NON-NUCLEOTIDE PHOSPHOROUS ESTER OLIGOMERS | PHARMAGENICS, INC. (US) | 1997-08-07 | — | — | WO | disclosed |
| WO-1996022297-A9 | NON-NUCLEOTIDE PHOSPHORUS ESTER OLIGOMERS | — | 1996-10-03 | — | — | WO | disclosed |
| WO-1996022297-A1 | NON-NUCLEOTIDE PHOSPHORUS ESTER OLIGOMERS | PHARMAGENICS, INC. (US) | 1996-07-25 | — | — | WO | disclosed |
| EP-0059158-B1 | AZA PROSTACYCLINS, THEIR PREPARATION AND THERAPEUTIC APPLICATIONS | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-08-03 | — | — | EP | disclosed |
| US-4567195-A | Azaprostacyclins, their preparation and pharmaceutical use | SCHERING, AKTIENGESELLSCHAFT (DE) | 1986-01-28 | — | — | US | disclosed |
| US-4446147-A | Azaprostacyclins, their preparation and pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-05-01 | — | — | US | disclosed |
| EP-0059158-A2 | Aza prostacyclins, their preparation and therapeutic applications | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318862-A1 | SYNTHESIS OF DELTA 12-PGJ3 AND RELATED COMPOUNDS | DGKZ, DGKG, DNAJA3 | MAPT 4401/4885ACE 4858/4885GABRA1 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.